Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMP1734 in Advanced Solid Tumors
NCT06253130Phase 2Recruiting
- Sponsor
- Eikon Therapeutics
- Start
- Dec 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of eik1003 in solid tumor (advanced stage), sponsored by Eikon Therapeutics. Primary endpoints: Adverse Events and Maximum Tolerated Dose at Cycle 1. Started Dec 2023; status: recruiting.
02
Drugs
eik1003
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06253130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253130.